386 related articles for article (PubMed ID: 26769569)
1. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
2. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
3. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
4. Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.
Kruger S; Haas M; Ormanns S; Bächmann S; Siveke JT; Kirchner T; Heinemann V; Boeck S
World J Gastroenterol; 2014 Aug; 20(31):10769-77. PubMed ID: 25152580
[TBL] [Abstract][Full Text] [Related]
5. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
[TBL] [Abstract][Full Text] [Related]
6. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
[TBL] [Abstract][Full Text] [Related]
8. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
[TBL] [Abstract][Full Text] [Related]
10. New Advances in the Treatment of Metastatic Pancreatic Cancer.
Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
Rubinson DA; Wolpin BM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
[TBL] [Abstract][Full Text] [Related]
12. Current and future biomarkers for pancreatic adenocarcinoma.
Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
[TBL] [Abstract][Full Text] [Related]
13. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.
Vuijk FA; de Muynck LDAN; Franken LC; Busch OR; Wilmink JW; Besselink MG; Bonsing BA; Bhairosingh SS; Kuppen PJK; Mieog JSD; Sier CFM; Vahrmeijer AL; Verheij J; Fariňa-Sarasqueta A; Swijnenburg RJ
Sci Rep; 2020 Oct; 10(1):16211. PubMed ID: 33004930
[TBL] [Abstract][Full Text] [Related]
14. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
[TBL] [Abstract][Full Text] [Related]
15. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
Byrne JD; Jajja MR; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2200-5. PubMed ID: 26858448
[TBL] [Abstract][Full Text] [Related]
16. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
[TBL] [Abstract][Full Text] [Related]
17. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
Lemstrova R; Melichar B; Mohelnikova-Duchonova B
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1101-1111. PubMed ID: 27250969
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer.
Sullivan KM; Kozuch PS
Cancer J; 2012; 18(6):633-41. PubMed ID: 23187852
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.
Winter JM; Yeo CJ; Brody JR
J Surg Oncol; 2013 Jan; 107(1):15-22. PubMed ID: 22729569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
